1. Introduction {#sec1}
===============

Cancer is one of the diseases caused by a combination of genetic and environmental factors \[[@B1]\]. The PON1 gene, located on the long arm of chromosome 7q21.3, is an antioxidant enzyme that has strong lipophilic antioxidant properties, which can maintain the balance of antioxidant-oxidant \[[@B2], [@B3]\]. Simultaneously, PON1 is also an esterase involved in scavenging reactive oxygen species by binding to high-density lipoprotein (HDL). Studies have shown that oxidative stress may participate in the process of cell proliferation and malignant transformation and damage DNA as well as other biological molecules, resulting in the occurrence of tumors \[[@B4]\]. The ability of PON1 detoxification of carcinogenic oxidative stress products makes it possible for researchers to predict PON1 gene polymorphism in cancer susceptibility \[[@B5]\].

At present, with the deep development of genetic studies of PON1, studies have found that PON1-Q192R and PON1-L55M, the two most common functional genetic polymorphisms in PON1, were identified at positions 192 and 55 \[[@B6]\]. PON1-Q192R polymorphism (rs662A \> G) was caused by the glutamine (Q genotype) substituted for the arginine (R genotype) 192 of the gene 6 exon of the PON 1 gene \[[@B7]\]. PON1-L55M (rs854560) was originated from the replacement of 55 leucines (L genotype) by methionine (M genotype) at third exon 55\[[@B8]\]. In addition, it has been shown that the two functional SNP, Q192R and L55M, were associated with the risk of multiple tumors \[[@B9], [@B10]\], such as oral cancer \[[@B11]\], lung cancer \[[@B12]\], and embryonal tumors \[[@B13]\].

According to the important role of PON1 in the development of tumor and the correlation between genotype and phenotype, we speculate that the variation of PON1 gene Q192 R and L55M may be related to tumor susceptibility. However, the data of many studies are contradictory and uncertain at present. Therefore, a comprehensive meta-analysis should be conducted to determine the relationship between Q192R and L55M polymorphism and cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We conducted a systematic literature search in the PubMed, Embase, and Web of Science for all related studies before June 10, 2019 via utilizing the following terms: "polymorphism OR paraoxonase 1 OR PON1" AND "tumor OR malignancy OR cancer OR carcinoma OR neoplasm". In addition, we extracted the reference of the original articles on this issue to carry out a hand search for extra studies. The results deduced from these articles were limited to humans. When the publication referred to more than one cancer type or ethnicity, we deled with data respectively. Besides, if different authors published articles based on the same population or one author used similar data in an article, we picked out the report with the latest study and largest sample size.

### 2.1.1. Inclusion Criteria and Exclusion Criteria {#sec2.1.1}

The enrolled studies must contain the following inclusion criteria: (1) publication that evaluated the association between PON1-L55M, or PON1-Q192R polymorphism and the risk of cancer. (2) The genotype frequency may be obtainable from cases and controls, or we could gain it via computing. In addition, studies were excluded when they would meet these exclusion criteria: (1) reviews, case reports, or case-only studies; (2) studies with deficient genotype frequency date; (3) animals reports; and (4) replicate studies.

2.2. Data Extraction {#sec2.2}
--------------------

The authors were able to excerpt relevant data from these qualified studies independently, and the following information would be seized: first author\'s last name, publishing year, the ethnicity of each population, the genotyping methods, the control of source, cancer types, number of cases and controls, and P value of Hardy--Weinberg equilibrium. When encountering divergences, we analyzed the report and reached a consistent agreement lastly.

2.3. Statistical Analysis {#sec2.3}
-------------------------

95% confidence interval (CI) and odds ratio (OR) were utilized to estimate the relation between PON1-Q192R, or PON1-L55M polymorphism and the risk of cancer with five genetic models: heterozygote comparison (ML versus LL; RQ versus QQ), allele contrast (M versus L; R versus Q), homozygote (MM versus LL; RR versus QQ), recessive (MM versus ML+LL; RR versus RQ+QQ), and dominant (ML+MM versus LL; RR+RQ versus QQ). Besides, stratified analyses were conducted via ethnicity, cancer type, control source, and genotyping method. However, when any cancer type is less than two studies, we would segment it into the "other cancers" group. In addition, *χ*^2^-test-based*Q-*statistic test \[[@B14]\] was taken to assess the research heterogeneity while *I*^2^ values and*P*values \[[@B15]\] were used for quantifying. When I^2^\< 50% and*P*\>0.10, it indicates that there was no significant heterogeneity, and ORs could be pooled by a fixed-effects model. Otherwise, the random effects model would be adopted \[[@B16]\]. Furthermore, sensitivity analysis, from the qualified removing a single research study and revealing the individual data set to merge OR influence, was applied to estimate the stability of these data. (*P*\<0.05 was regarded as statistically significant \[[@B17]\].) Finally, potential publication bias was estimated by symmetry of funnel plot of Begg\'s test as well as Egger\'s test \[[@B15], [@B18]\], and being statistically significant was considered when P\<0.05. All statistical tests were performed with STATA Software (version 14.0, state Corp), and*P*\<0.05 for any genetic models or tests was identified as statistically significant.

3. Result {#sec3}
=========

3.1. Publication Characteristics {#sec3.1}
--------------------------------

According to the inclusion criteria after detailed examination, a total of 43 case-control publications including 19977 cases and 23932 controls were employed in our study \[[@B11]--[@B13], [@B19]--[@B61]\]. The flow chart of the study screening process was summarized in [Figure 1](#fig1){ref-type="fig"}. Moreover, there were 43 studies with 11412 cases and 13936 controls for PON1-Q192R polymorphism ([Table 1](#tab1){ref-type="table"}), and, for*PON1*L55M polymorphism, 28 studies involved a total of 8565 cases and 9996 controls ([Table 2](#tab2){ref-type="table"}). For*PON1*Q192R polymorphism, a total of 8 cancer types were processed, including breast cancer \[[@B21], [@B28], [@B32], [@B33], [@B38], [@B40], [@B52]\], prostate cancer \[[@B22], [@B23], [@B41], [@B42]\], gastrointestinal cancer \[[@B19], [@B20], [@B50], [@B61], [@B63]\], hematologic tumor \[[@B25], [@B30], [@B34], [@B46]\], lung cancer \[[@B11], [@B12], [@B56]\], brain tumors \[[@B31], [@B36], [@B39], [@B47], [@B58], [@B59]\], ovarian cancer \[[@B35], [@B45]\] and other cancers \[[@B13], [@B27], [@B29], [@B43], [@B55], [@B60]\] (uterine leiomyoma, childhood embryonal tumors, metastatic gastric cancer, bladder cancer, and renal cell cancer). Besides, we disposed a total of 7 cancer types when dealing with PON1-L55M polymorphism nearly like PON1 Q192R polymorphism. In addition, For*PON1*Q192R polymorphism, 9 publications were conducted in Asians, 9 in mixed group, and 25 publications in Caucasians. Besides, there were 15 studies divided by TaqMan assay, while 28 studies conducted by PCR- RFLP. Moreover, the majority of control groups in the case group are gender and age matching, including 23 hospital based and 20 population based. For*PON1*L55M polymorphism, we also conducted 6, 6, and 16 studies in Asian, mixed group, Caucasians, respectively. Moreover, 10 studies were divided by TaqMan assay as well as 18 studies conducted by PCR- RFLP.

3.2. Meta-Analysis {#sec3.2}
------------------

### 3.2.1. Association between PON1-Q192R and Cancer Susceptibility {#sec3.2.1}

In summary, in allele contrast model, we have found that there were not association between PON1-Q192R allele and reduced overall cancer risk ([Table 3](#tab3){ref-type="table"}). In the subgroup analysis of cancer type, we identified a decreased risk in breast cancer (R versus Q: OR=0.643, 95%CI=0.440-0.942; RR versus QQ: OR=0.542, 95%CI=0.331-0.886; RQ versus QQ: OR=0.529, 95%CI=0.325-0.861; and RR+RQ versus QQ: OR=0.534, 95%CI=0.330-0.865). Nevertheless, an increased risk was confirmed in prostate cancer in the dominant model (RR+RQ versus QQ: OR=1.249, 95%CI=1.030-1.514). Furthermore, by racial stratification, there was a reduced risk of cancer in recession model (RR+RQ versus QQ: OR=0.744, 95%CI=0.557-0.993) among Caucasian population. Similarly, in the stratification analysis of control source, the overall risk of cancer is reduced in the heterozygote comparison and dominant model (RQ versus QQ: OR= 0.793, 95%CI=0.638-0.984; RR+RQ versus QQ: OR=0.789, 95%CI=0.630-0.988) in the population-based group. In addition, we did not observe any risk factor by stratified analysis using genotyping method. [Figure 2](#fig2){ref-type="fig"} showed the meta-analysis of the association between PON1-Q192R polymorphism and cancer risk (R versus Q)

### 3.2.2. Association between PON1-L55M and Cancer Susceptibility {#sec3.2.2}

Our study had uncovered that the PON1-L55M polymorphism was significantly associated with an increased risk of the overall cancers under all the genetic models ([Table 4](#tab4){ref-type="table"}) (M versus L: OR =1.277, 95% CI =1.127-1.448; MM versus LL: OR =1.507, 95% CI =1.205-1.885; ML versus LL: OR =1.192, 95%CI =1.064-1.337; MM versus ML+LL: OR =1.288, 95%CI =1.120-1.408; ML+MM versus LL: OR =1.417, 95%CI =1.176-1.708). Furthermore, we found an increased risk of breast cancer under all the five models when conducting the cancer type subgroup analysis (M versus L: OR =2.186, 95%CI =1.438-3.323; MM versus LL: OR =3.215, 95%CI=1.756-5.886; ML versus LL: OR =1.579, 95%CI=1.145-2.177; MM versus ML+LL: OR =2.727, 95%CI=1.563-4.756; ML+MM versus LL: OR =2.110, 95%CI =1.397-3.188), prostate cancer in the dominant and heterozygote comparison model (ML versus LL: OR =1.291, 95% CI =1.071-1.557; ML+MM versus LL: OR =1.341, 95%CI=1.024-1.756), and hematologic tumor in the allele contrast model (M versus L: OR =1.271, 95% CI =1.059-1.525), homozygote model (MM versus LL: OR =1.514, 95%CI =1.178-1.946), recessive model (MM versus ML+LL: OR =1.405, 95%CI =1.111-1.778), and dominant model (ML+MM versus LL: OR =1.299, 95%CI =1.017-1.661). [Figure 3](#fig3){ref-type="fig"} showed the meta-analysis of the association between PON1-L55M polymorphism and cancer risk (M versus L).

Similarly, an increased risk was observed in the Caucasian population under the five genetic models: M versus L: OR =1.231, 95% CI = 1.028-1.474; MM versus LL: OR =1.737, 95% CI =1.519-1.986; ML versus LL: OR =1.170, 95% CI =1.034-1.324; MM versus ML+LL: OR =1.407, 95%CI =1.092-1.813; ML+MM versus LL: OR =1.334, 95%CI =1.215-1.465, the Asian population (M versus L: OR =1.604, 95% CI =1.089-2.363; MM versus LL: OR =2.093, 95% CI =1.295-3.381; ML versus LL: OR =1.550, 95% CI =0.995-2.417; MM versus ML+LL: OR =1.624, 95%CI =1.041-2.535; ML+MM versus LL: OR =1.967, 95%CI =1.238-3.125), the mixed population (M versus L: OR =1.177, 95%CI =1.004-1.379; ML+MM versus LL: OR =1.126, 95%CI =1.006-1.261) ([Table 4](#tab4){ref-type="table"}), hospital-based group (M versus L: OR =11.240, 95%CI=1.056-1.456; MM versus LL: OR =1.531, 95%CI =1.199-1.955; ML versus LL: OR =1.255, 95%CI =1.020-1.543; MM versus ML+LL: OR =1.288, 95%CI =1.120-1.480; ML+MM versus LL: OR =1.411, 95%CI=1.173-1.698), and population-based group (M versus L: OR =1.325, 95%CI=1.085-1.618; MM versus LL: OR =1.568, 95%CI =1.091-2.253; ML versus LL: OR =1.275, 95%CI =1.051-1.548; MM versus ML+LL: OR =1.503, 95%CI =1.110-2.034; ML+MM versus LL: OR =1.222, 95%CI=1.122-1.331). In addition, we identified an increased risk by stratified analysis using genotyping method.

### 3.2.3. Publication Bias and Sensitivity Analysis {#sec3.2.3}

A sensitivity analysis was carried out to detect the impact of individual papers on whole data by getting rid of one report at a time from the pooled analysis. And no individual report has been significantly affected by the pooled OR. [Figure 4](#fig4){ref-type="fig"} showed the plot of the sensitivity analysis for evaluating the association between PON1-Q192R and cancer risk (RR versus QQ). Besides, we perform Egger\'s test and Begg\'s funnel plot to evaluate publication bias ([Figure 5](#fig5){ref-type="fig"}). And the results of Egger\'s test and Begg\'s funnel plot did not uncover publication bias in PON1 (Q192R and L55M) gene polymorphisms (PON1 Q192R: R versus Q: Begg\'s test: z=1.74 P=0.082; Egger\'s test: t= -1.26 P=0.216; PON1-L55M: M versus L: Begg\'s test: z=0.06 p=0.953; Egger\'s test: t= 0.66; P=0.516). Thus, our results are believable due to the absence of significant publication bias in our meta-analysis.

4. Discussion {#sec4}
=============

Several studies have indicated that PON1, which is one of xenobiotic metabolising enzymes, plays a crucial role in the detoxification of carcinogenic compounds and decreases oxidative stress. Genetic polymorphisms can influence the enzyme and modify its activity, resulting in an impact on individual sensitivity to certain pathologies \[[@B64]\]. Indeed, a great deal of researches have showed that polymorphisms encoding the gene of these enzymes have been linked to the progression of cancer \[[@B51], [@B65]\]. Furthermore, several variants of PON1, including Q192R and L55M, have been found to be a biologically reasonable candidate which has an obvious influence on cancer. PON1 (Q192R and L55M) gene polymorphisms were related to many types of cancer, such as breast, prostate, and hepatocellular carcinoma \[[@B20], [@B52], [@B67]\]. For instance, PON1-L55M polymorphism may increase the risk in multiple cancer types, such as prostate and breast cancers but decrease renal cell carcinoma and ovarian cancer risk. As for PON1-Q192R, it has been revealed to suppress expression in lung \[[@B68]\] and pancreatic cancer \[[@B69]\] and reduce the risk of breast and prostate cancers. And the results of these researches were inconclusive and controversial.

In our work, in all genetic models we have identified the significant association between PON1-L55M polymorphism and overall cancer risk, while PON1-Q192R allele was not associated with reduced overall cancer risks. In the stratified analysis, we observed an increased risk in the Caucasian population and the Asian population, as well as the hospital-based group and population-based group under all the five genetic models in the PON1-L55M polymorphism. Similarly, a significantly increased risk of the overall cancers under the homozygote, allele contrast, recessive, and dominant models was uncovered in hematological tumor in the PON1-L55M polymorphism. Nevertheless, in the PON1-Q192R polymorphism, we also observe a reduced risk of the overall cancers in the allele contrast and dominant models. Meanwhile, we could obtain an interesting phenomenon that PON1-L55M polymorphism acts as a risk factor in all the five genetic models and there was an association between Q192R polymorphism and a reduced risk for cancer progression (except recessive model) after stratified analyses by cancer type, especially breast cancer. Thus, we can obtain that PON1 (Q192R and L55M) gene polymorphisms play a vital role in the development of breast cancer, whose mechanism maybe as follows: there was a critical association between L allele and higher PON1 serum concentrations while M variant decreased the stability of this enzyme. Therefore, the blood concentration of PON1 was reduced in this way; then, the activity of the enzyme was influenced, which may increase the vulnerability to genomic damage by reducing the inflammatory oxidant and the detoxifying ability of dietary carcinogens, thereby increasing the risk of breast cancer \[[@B5]\]. Furthermore, breast cancer becomes more susceptible to genomic damage as a result of lower levels of PON1 which could decrease the ability to detoxify inflammatory oxidants and dietary carcinogens \[[@B5]\]. Similarly, the exchange of Q and R could produce an enzyme which has a higher detoxification activity when there were potential carcinogenic products of oxidative stress and lipid peroxidation \[[@B70], [@B71]\]. In addition, not only genetic factors but also other contributors including nutrition and lifestyle can significantly affect PON1 enzyme activity, thereby reducing the risk of breast cancer \[[@B72]\]. To sum up, PON1, as a member of lipid peroxidation scavenging systems, may have an impact on malignant transformation and cell proliferation in the progression of breast cancer \[[@B73]\]. In the ethnographic analysis, we found ethnic groups having different results, which may be due to ethnic living habits, living environment, and genetic factors.

Previous meta-analysis also reported the association of PON1 polymorphism with cancer risk \[[@B10], [@B74]\]. As far as we know, we are the first of the typical functional polymorphism of the PON1 gene including all the published and defined case-control studies that have been conducted in a comprehensive meta-analysis. Compared with previous researches, our report was more persuasive and we have carried out a more detailed analysis to demonstrate our results. First and most obviously, the data we collected in our study was up-to-date, and we could keep up with the research front. Secondly, we included more qualified studies and larger sample size, which indicates that we are relatively more accurate in assessing that association between the PON1 gene SNPs and the risk of cancer.

Despite the association between PON1 (Q192R and L55M) gene polymorphism and cancer risk which has been studied in detail, we should note some limitations at the same time. First of all, the quantity of publications collected in our study was limited and there was a relatively small sample size of the report. What is more, Caucasian accounted for the most of the registered publications and there were no Africans. Furthermore, some of publications would only publish positive results, which could make the meta-analysis less credible. Lastly, our results were based on the estimates of single-factor, which could lead to serious confusion and bias due to the lack of raw data, and there is a need to adjust the effect size with possible confounders related to lifestyle risk factors, such as age, obesity, alcohol consumption, and smoking.

In conclusion, our study has demonstrated that PON1-Q192R can significantly reduce the risk of cancer and the polymorphism of PON1-L55M is a risk factor leading to cancer, especially breast cancer. Next, we need a larger sample size at protein levels to confirm whether PON1 polymorphisms may be potential genetic markers of tumor prognosis and identify its role in the risk of women developing breast cancer.
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![Flow chart of the report selection process.](BMRI2019-5897505.001){#fig1}

![Meta-analysis of the association between PON1-Q192R polymorphism and cancer risk (R versus Q). Abbreviations: ID, identification; CI, confidence interval; NA, not available; OR, odds ratio; weights come from random effects analysis.](BMRI2019-5897505.002){#fig2}

![Meta-analysis of the association between PON1-L55M polymorphism and cancer risk (M versus L). Abbreviations: ID, identification; CI, confidence interval; NA, not available; OR, odds ratio; weights come from random effects analysis.](BMRI2019-5897505.003){#fig3}

![Sensitivity analysis of PON1-Q192R in overall OR coefficients (RR versus QQ). Abbreviations: OR, odds ratio CI, confidence interval. Sequentially calculated results of each study are omitted. Both ends of the broken line represent 95% of the CI.](BMRI2019-5897505.004){#fig4}

![Funnel figure of PON1-Q192R in overall OR coefficients (RR versus QQ). Abbreviations: OR, odds ratio.](BMRI2019-5897505.005){#fig5}

###### 

Characteristics of qualified case-control studies included in the meta-analysis of PON1-Q192R.

  Author                       Year   Ethnicity   Genotyping Method   Control of source   Cancer Type                Case   Control   HWE                                        
  ---------------------------- ------ ----------- ------------------- ------------------- -------------------------- ------ --------- ----- ----- ----- ----- -------- --------- ---
  Stevens et al.               2006   Caucasian   PCR-RFLP            P-B                 Breast Cancer              259    182       42    238   198   47    0.38     0.54      Y
  Gallicchio et al.            2007   Caucasian   PCR-RFLP            P-B                 Breast Cancer              38     15        5     469   353   82    1.93     0.19      Y
  Antognelli et al.            2009   Caucasian   PCR-RFLP            P-B                 Breast Cancer              484    50        13    340   152   52    27.19    0.00      N
  Hussein et al.               2011   Caucasian   PCR-RFLP            P-B                 Breast Cancer              51     41        8     46    42    12    0.25     0.62      Y
  Naidu et al.                 2010   Asian       PCR-RFLP            H-B                 Breast Cancer              200    158       29    115   115   22    0.81     0.37      Y
  Tang et al.                  2017   Asian       TaqMan              P-B                 Esophagogastric            408    501       132   691   776   207   0.23     0.63      Y
  Uluocak et al.               2017   Caucasian   PCR-RFLP            H-B                 Prostate Cancer            24     17        8     45    42    11    0.06     0.80      Y
  Wu et al.                    2017   Asian       TaqMan              H-B                 Breast Cancer              155    156       54    167   156   55    3.42     0.06      Y
  Kaya et al.                  2016   Caucasian   TaqMan              H-B                 Breast Cancer              10     11        11    5     13    17    0.88     0.35      Y
  Tomatir et al.               2015   Caucasian   PCR-RFLP            H-B                 Hematologic Cancer         36     20        4     58    24    2     0.07     0.79      Y
  Tomatir et al.               2015   Caucasian   PCR-RFLP            H-B                 Hematologic Cancer         33     21        6     58    24    2     0.07     0.08      Y
  Attar et al.                 2015   Caucasian   PCR-RFLP            H-B                 Uterine Leiomyoma          60     8         8     50    47    6     1.39     0.24      Y
  Eom et al.                   2015   Asian       PCR-RFLP            H-B                 Lung Cancer                37     170       209   48    188   180   0.01     0.92      Y
  Ahmed et al.                 2015   Asian       PCR-RFLP            P-B                 Colorectal Cancer          30     16        4     20    36    24    0.76     0.38      Y
  Akkız et al.                 2013   Caucasian   PCR-RFLP            P-B                 Hepatocellular Carcinoma   109    95        13    115   88    14    0.27     0.60      Y
  Vasconcelos et al.           2014   Mixed       TaqMan              H-B                 Embryonal Tumors           36     85        41    104   160   72    0.51     0.48      Y
  Conesa-Zamora et al.         2013   Caucasian   TaqMan              H-B                 Lymphomas                  83     99        33    100   104   10    7.00     0.01      N
  Zhao et al.                  2012   Asian       TaqMan              H-B                 Glioma                     161    158       52    159   167   52    0.59     0.44      Y
  De Aguiar Goncalves et al.   2012   Mixed       TaqMan              H-B                 Hematologic Tumor          96     102       40    74    106   54    1.790    0.180     Y
  Kokouva et al.               2012   Caucasian   PCR-RFLP            H-B                 Hematologic Cancer         213    88        15    181   141   29    0.04     0.83      Y
  Aksoy-Sagirli et al.         2011   Caucasian   PCR-RFLP            H-B                 Lung Cancer                93     111       19    121   93    20    0.13     0.72      Y
  Uyar et al.                  2011   Caucasian   PCR-RFLP            P-B                 Renal Cell Cancer          38     21        1     27    27    6     0.04     0.84      Y
  Lurie et al.                 2008   Mixed       TaqMAN              P-B                 Ovarian Cancer             66     120       86    122   211   111   1.07     0.30      Y
  Ergen et al.                 2010   Caucasian   PCR-RFLP            H-B                 Osteosarcoma               27     21        2     15    33    2     0.06     0.80      Y
  Martinez et al.              2010   Caucasian   TaqMan              H-B                 Brain Tumor                31     33        9     22    89    109   0.37     0.54      Y
  Ozturk et al.                2009   Caucasian   PCR-RFLP            H-B                 Bladder Cancer             8      53        15    37    84    14    10.71    \<0.001   N
  Gold et al.                  2009   Mixed       PCR-RFLP            P-B                 Multiple Myeloma           10     19        13    9     27    19    0.01     0.91      Y
  Arpaci et al.                2009   Caucasian   PCR-RFLP            H-B                 Ovarian Cancer             38     6         6     17    29    6     1.46     0.23      Y
  Rajaraman et al.             2008   Mixed       TaqMan              H-B                 Brain Tumor                266    207       39    244   165   44    4.10     0.04      N
  Searles Nielsen et al.       2005   Mixed       TaqMan              P-B                 Brain Tumor                32     28        6     100   105   31    0.17     0.68      Y
  Van der Logt et al.          2005   Caucasian   PCR-RFLP            P-B                 Colorectal Cancer          180    150       24    158   120   17    0.87     0.35      Y
  Lincz et al.                 2004   Caucasian   PCR-RFLP            P-B                 Multiple Myeloma           33     41        16    103   74    22    2.35     0.13      Y
  Kerridge et al.              2002   Caucasian   PCR-RFLP            P-B                 Lymphoma                   73     50        39    103   74    22    2.35     0.13      Y
  Antognelli et al.            2005   Caucasian   PCR-RFLP            H-B                 Prostate Cancer            197    168       20    212   85    64    67.85    \<0.001   N
  Herrera et al.               2015   Mixed       TaqMan              H-B                 Brain Tumor                15     32        20    12    32    14    0.64     0.42      Y
  Kafadar et al.               2006   Caucasian   PCR-RFLP            H-B                 Brain Tumor                43     26        15    24    18    8     1.96     0.16      Y
  J. De Roos et al.            2006   Mixed       TaqMan              P-B                 Hematologic Cancer         540    453       127   415   403   117   1.53     0.22      Y
  Stevens et al.               2008   Mixed       TaqMan              P-B                 Prostate Cancer            624    537       95    656   487   121   4.74     0.03      N
  Antognelli et al.            2013   Caucasian   PCR-RFLP            H-B                 Prostate Cancer            291    250       30    707   258   203   244.08   \<0.001   N
  Wang et al.                  2012   Asian       PCR-RFLP            P-B                 Lung Cancer                36     177       143   38    84    62    0.93     0.33      Y
  Lee et al.                   2005   Asian       TaqMan              P-B                 Lung Cancer                24     80        73    11    89    77    4.999    0.025     N
  Agachan et al.               2006   Caucasian   PCR-RFLP            P-B                 Breast Cancer              17     4         12    6     29    17    1.461    0.230     Y
  Hemati et al.                2019   Asian       PCR-RFLP            H-B                 Gastric Cancer             39     41        10    62    26    2     0.03     0.87      Y

*Abbreviations*: PCR-RFlP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium; Y, polymorphisms conforming to HWE in the control group; N, polymorphisms not conforming to HWE in the control group; H-B, hospital based; P-B, population based.

###### 

Characteristics of qualified case-control studies included in the meta-analysis of PON1- L55M.

  Author                       Year   Ethnicity   Genotyping Method   Control of source   Cancer Type                 Case   Control   HWE                                       
  ---------------------------- ------ ----------- ------------------- ------------------- --------------------------- ------ --------- ----- ------ ----- ----- ------- -------- ---
  Stevens et al.               2006   Caucasian   PCR-RFLP            P-B                 Breast Cancer               176    230       77    202    233   58    0.88    0.77     Y
  Antognelli et al.            2009   Caucasian   PCR-RFLP            P-B                 Breast Cancer               107    115       325   188    125   231   157.2   0.0001   N
  Hussein et al.               2011   Caucasian   PCR-RFLP            P-B                 Breast Cancer               19     21        60    35     23    6     0.58    0.44     Y
  Naidu et al.                 2010   Asian       PCR-RFLP            P-B                 Breast Cancer               159    178       50    126    109   17    1.04    0.308    Y
  Tang et al.                  2017   Asian       TaqMan              P-B                 Esophagogastric Cancer      971    69        1     1573   99    2     0.12    0.73     Y
  Uluocak et al.               2017   Caucasian   PCR-RFLP            H-B                 Prostate Cancer             19     24        6     43     45    10    0.13    0.72     Y
  Wu et al.                    2017   Asian       TaqMan              H-B                 Breast Cancer               284    72        9     346    30    2     3.24    0.064    Y
  Akkız et al.                 2013   Caucasian   PCR-RFLP            P-B                 Hepatocellular Carcinoma    105    81        31    101    89    27    1.12    0.29     Y
  Geng R et al.                2014   Asian       TaqMan              H-B                 Metastatic Gastric Cancer   11     7         0     82     7     0     0.15    0.7      Y
  Vasconcelos et al.           2014   Mixed       TaqMan              H-B                 Embryonal Tumors            85     56        15    177    134   25    0.023   0.95     Y
  Metin et al.                 2013   Caucasian   PCR-RFLP            H-B                 Ovarian Cancer              33     22        0     33     19    2     0.13    0.72     Y
  Vecka et al.                 2012   Caucasian   PCR-RFLP            H-B                 Pancreatic Cancer           24     39        10    28     37    8     0.67    0.41     Y
  De Aguiar Goncalves et al.   2012   Mixed       TaqMan              H-B                 Acute Leukemia              104    99        34    131    75    19    2.91    0.09     Y
  Kokouva et al.               2012   Caucasian   PCR-RFLP            H-B                 Hematologic Cancer          117    139       60    142    159   50    0.26    0.61     Y
  Aksoy-Sagirli et al.         2011   Caucasian   PCR-RFLP            H-B                 Lung Cancer                 119    94        10    118    102   14    1.75    0.19     Y
  Uyar et al.                  2011   Caucasian   PCR-RFLP            P-B                 Renal Cell Cancer           29     25        6     21     29    10    4.96    0.998    Y
  Lurie et al.                 2008   Mixed       TaqMan              P-B                 Ovarian Cancer              14     65        192   24     145   276   0.74    0.39     Y
  Ergen et al.                 2010   Caucasian   PCR-RFLP            H-B                 Osteosarcoma                24     23        3     21     20    9     1.14    0.29     Y
  Martínez et al.              2010   Caucasian   TaqMan              H-B                 Brain Tumor                 11     32        30    38     94    88    2.15    0.14     Y
  Arpaci et al.                2009   Caucasian   PCR-RFLP            H-B                 Ovarian Cancer              27     19        5     25     27    2     2.65    0.103    Y
  Van der Logt et al.          2005   Caucasian   PCR-RFLP            P-B                 Colorectal Cancer           139    166       59    140    162   50    0.08    0.78     Y
  Antognelli et al.            2005   Caucasian   PCR-RFLP            H-B                 Prostate Cancer             120    197       67    148    169   43    0.65    0.35     Y
  Herrera et al.               2015   Mixed       TaqMan              H-B                 Brain Tumor                 46     17        4     42     14    2     0.37    0.56     Y
  J. De Roos et al.            2006   Mixed       TaqMan              P-B                 Hematologic Cancer          299    307       100   282    260   69    0.59    0.44     Y
  Stevens et al.               2008   Mixed       TaqMan              P-B                 Prostate Cancer             481    609       165   498    575   189   1.18    0.28     Y
  Wang et al.                  2012   Asian       PCR-RFLP            P-B                 Lung Cancer                 307    47        2     166    18    0     0.49    0.49     Y
  Antognelli et al.            2013   Caucasian   PCR-RFLP            H-B                 Prostate Cancer             180    291       100   497    540   131   0.75    0.39     Y
  Hemati et al.                2019   Asian       PCR-RFLP            H-B                 Gastric Cancer              41     40        9     34     49    7     0.027   0.87     Y

*Abbreviations*: PCR-RFlP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium; Y, polymorphisms conforming to HWE in the control group; N, polymorphisms not conforming to HWE in the control group; H-B, hospital based; P-B, population based.

###### 

Results of meta-analysis for PON1-Q192R polymorphism and cancer risk.

  Variables                  Case/control   R vs. Q                  RR vs. QQ   RQ vs. QQ   RR+RQ vs. QQ            RR vs. RQ+QQ                                                                                                                     
  -------------------------- -------------- ------------------------ ----------- ----------- ----------------------- -------------- ------ ----------------------- ------- ------ ----------------------- ------- ------ -------------------- ------- ------
  Total                      11412/13936    0.897(0.798-1.008)       0           86.8        0.855(0.683-1.073)      0              81.1   0.861(0.724-1.023)      0       86.7   0.857(0.730-1.008)      0       86.7   0.914(0.758-1.102)   0       78.1
   Breast cancer             2005/2748      0.643(0.440-0.942) *∗*   0           91.4        0.542(0.331-0.886)*∗*   0              74     0.529(0.325-0.861)*∗*   0       89.1   0.534(0.330-0.865)*∗*   0       90.6   0.720(0.492-1.054)   0.010   62.3
   Gastrointestinal cancer   1752/2356      1.008(0.700-1.450)       0           88.1        0.969(0.463-2.025)      0.000          80.2   1.079(0.761-1.529)      0.002   75.7   1.038(0.682-1.580)      0.000   85.0   0.968(0.547-1.711)   0.013   68.5
   Prostate cancer           2261/2891      0.967(0.886-1.055)       0.748       0           0.563(0.313-1.015)      0.001          83     1.544(0.969-2.458)      0       90.9   1.249(1.030-1.514)*∗*   0.083   55     0.498(0.235-1.053)   0       90.3
   Hematologic tumor         2303/2355      1.113(0.852-1.453)       0           85.5        1.358(0.787-2.341)      0              82     0.943(0.740-1.202)      0.007   62.3   1.040(0.774-1.397)      0       78.2   1.364(0.863-2.157)   0       77.8
   Lung cancer               1172/1011      1.179(0.949-1.464)       0.04        63.8        1.244(0.665-2.326)      0.005          76.6   1.214(0.704-2.094)      0.004   77.5   1.262(0.741-2.149)      0.003   78.6   1.201(0.997-1.449)   0.442   0
   Brain tumor               1173/1395      0.759(0.505-1.140)       0           89.2        0.576(0.266-1.248)      0              85.9   0.778(0.539-1.124)      0.006   69     0.696(0.431-1.123)      0       84.4   0.698(0.388-1.256)   0       79.4
   Ovarian cancer            322/496        0.665(0.189-2.337)       0           92.7        0.940(0.314-2.813)      0.087          65.8   0.328(0.030-3.572)      0       94.6   0.443(0.060-3.283)      0       94.5   1.359(0.985-1.875)   0.658   0
   Other cancers             424/684        0.809(0.481-1.362)       0           85.1        1.264(0.515-3.101)      0.022          65     0.670(0.250-1.798)      0       89.4   0.741(0.299-1.838)      0       89.1   1.352(0.797-2.294)   0.209   31.8
  Ethnicities                                                                                                                                                                                                                                          
   Caucasian                 4424/6292      0.815(0.658-1.011)       0           90.1        0.784(0.516-1.193)      0              84.5   0.731(0.528-1.010)      0       91.1   0.744(0.557-0.993)*∗*   0       90.3   0.893(0.608-1.311)   0       83.5
   Asian                     3253/3629      0.840(0.840-1.244)       0           89.9        1.019(0.689-1.506)      0              78.5   1.020(0.779-1.337)      0       76.3   1.022(0.758-1.377)      0       83.0   1.052(0.850-1.303)   0.025   54.4
   Mixed                     3735/4015      0.981(0.877-1.098)       0.035       51.6        0.913(0.727-1.145)      0.062          46.2   1.012(0.873-1.174)      0.109   38.8   0.990(0.851-1.153)      0.057   47     0.929(0.770-1.119)   0.115   38.1
  Control source                                                                                                                                                                                                                                       
   Population based          6871/8354      0.849(0.717-1.004)       0           88.8        0.802(0.604-1.065)      0              79.1   0.793(0.638-0.984)*∗*   0       85     0.789(0.630-0.988)*∗*   0       87.9   0.920(0.749-1.130)   0       70.3
   Hospital based            4309/5667      0.897(0.798-1.008)       0           85.1        0.948(0.655-1.374)      0              83.2   0.927(0.704-1.221)      0       87.3   0.923(0.726-1.175)      0       85.5   0.967(0.696-1.342)   0       83.3
  Genotype method                                                                                                                                                                                                                                      
   PCR-RFLP                  5445/6900      0.884(0.735-1.064)       0           88.4        0.888(0.735-1.064)      0              88.4   0.815(0.607-1.094)      0       90.4   0.839(0.646-1.091)      0       89.4   0.938(0.692-1.271)   0       80.5
   TaqMan                    5967/7036      0.922(0.801-1.060)       0           83          0.834(0.622-1.117)      0              81.3   0.952(0.824-1.099)      0.001   61.1   0.906(0.762-1.078)      0       76.7   0.915(0.736-1.139)   0       73.5

Notes: *∗* statistically significant (P\<0.05); P value^a^: P value of Q test for heterogeneity test; I^2^: 0%--25% means no heterogeneity, 25%--50% means modest heterogeneity, and 50% means high heterogeneity. Abbreviations: CI, confidence interval; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

Results of meta-analysis for PON1-L55M polymorphism and cancer risk.

  Variables                 Case/control   M vs. L                  MM vs. LL   ML vs. LL   ML+MM vs. LL            MM vs. ML+LL                                                                                                                         
  ------------------------- -------------- ------------------------ ----------- ----------- ----------------------- -------------- ------ ------------------------ ------- ------ ----------------------- ------- ------ ----------------------- ------- ------
  Total                     8565/9996      1.277(1.127-1.448)*∗*    0           81.6        1.507(1.205-1.885)*∗*   0              68.5   1.192(1.064-1.337)*∗*    0.001   50.6   1.288(1.120-1.480)*∗*   0       70.9   1.417(1.176-1.708)*∗*   0       64.2
  Breast cancer             1882/1731      2.186(1.438-3.323) *∗*   0           92.5        3.215(1.756-5.886)*∗*   0              81.8   1.579(1.145-2.177) *∗*   0.01    69.9   2.110(1.397-3.188)*∗*   0       85.3   2.727(1.563-4.756)*∗*   0       81.9
  Gastrointestinal cancer   1803/2495      1.111(0.898-1.375)       0.071       50.7        1.165(0.848-1.601)      0.988          0      1.097(0.794-1.515)       0.023   61.5   1.120(0.829-1.512)      0.032   59.0   1.185(0.881-1.594)      0.996   0
  Prostate cancer           2259/2888      1.233(0.971-1.566)       0           84.3        1.496(0.876-2.556)      0              85.5   1.291(1.071-1.557)*∗*    0.144   44.6   1.341(1.024-1.756)*∗*   0.008   74.6   1.284(0.838-1.966)      0.002   80.5
  Hematologic tumor         1259/1187      1.271(1.059-1.525)*∗*    0.121       52.7        1.514(1.178-1.946)*∗*   0.376          0      1.212(0.954-1.540)       0.172   43.1   1.299(1.017-1.661)*∗*   0.124   52     1.405(1.111-1.778)*∗*   0.622   0
  Ovarian cancer            377/553        1.219(0.965-1.539)       0.450       0           1.208(0.648-2.253)      0.393          0      0.833(0.536-1.296)       0.579   0      0.952(0.623-1.454)      0.802   0      1.482(0.800-2.743)      0.316   13.2
  Lung cancer               579/418        1.095(0.666-1.801)       0.104       62.2        0.781(0.344-1.771)      0.404          0      1.074(0.711-1.622)       0.215   34.8   1.089(0.670-1.767)      0.146   52.7   0.806(0.361-1.799)      0.432   0
  Other cancers             406/724        0.932(0.753-1.155)       0.333       12.6        0.884(0.505-1.548)      0.215          31     0.907(0.682-1.206)       0.801   0      0.910(0.696-1.190)      0.625   0      0.930(0.584-1.481)      0.252   25.4
  Ethnicities                                                                                                                                                                                                                                             
  Caucasian                 3616/4392      1.231(1.028-1.474)*∗*    0           83.8        1.737(1.519-1.986)*∗*   0              72     1.170(1.034-1.324)*∗*    0.199   22.4   1.334(1.215-1.465)*∗*   0       70.7   1.407(1.092-1.813)*∗*   0       67.8
  Asian                     2257/2667      1.604(1.089-2.363)*∗*    0           80.7        2.093(1.295-3.381)*∗*   0.441          0      1.550(0.995-2.417)       0.000   79.7   1.624(1.041-2.535)*∗*   0       80.8   1.967(1.238-3.125)*∗*   0.656   0
  Mixed                     2692/2937      1.177(1.004-1.379)*∗*    0.019       63.1        1.137(0.955-1.354)      0.088          47.8   1.112(0.953-1.297)       0.268   22.1   1.126(1.006-1.261)*∗*   0.165   36.3   1.262(0.957-1.665)      0.034   58.4
  Control source                                                                                                                                                                                                                                          
  Population based          5787/6158      1.325(1.085-1.618)*∗*    0           88.7        1.568(1.091-2.253)*∗*   0              81.9   1.275(1.051-1.548)*∗*    0.401   4.5    1.275(1.051-1.548)*∗*   0       75.7   1.503(1.110-2.034)*∗*   0       80.5
  Hospital based            2778/3838      1.240(1.056-1.456)*∗*    0           68.9        1.531(1.199-1.955)*∗*   0.132          29.8   1.255(1.020-1.543)*∗*    0.000   62.3   1.288(1.120-1.480)*∗*   0       66.7   1.411(1.173-1.698)*∗*   0.324   11.6
  Genotype method                                                                                                                                                                                                                                         
  PCR-RFLP                  4376/4698      1.243(1.053-1.466)*∗*    0           82.2        1.571(1.183-2.087)*∗*   0              70.1   1.164(1.033-1.311)*∗*    0.145   26.5   1.246(1.045-1.487)*∗*   0       69.3   1.483(1.167-1.884)*∗*   0       62.7
  TaqMan                    4189/5298      1.330(1.091-1.622)*∗*    0           79.5        1.309(0.988-1.735)      0.091          41.4   1.307(1.026-1.665)*∗*    0.001   71.5   1.370(1.073-1.748)*∗*   0       74.7   1.264(0.986-1.620)*∗*   0.05    48.5

Notes: *∗* statistically significant (P\<0.05); P value^a^: P value of Q test for heterogeneity test; I^2^: 0%--25% means no heterogeneity, 25%--50% means modest heterogeneity, and 50% means high heterogeneity.

Abbreviations: CI, confidence interval; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.
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